Cisplatin and Etoposide for Advanced Ovarian Cancer
Author Information
Author(s): A.E. Athanassiou, D. Bafaloukos, D. Pectasides, M. Dimitriadis, I. Varthalitis, V. Barbounis
Primary Institution: Metaxas Memorial Cancer Hospital
Hypothesis
Does the combination of cisplatin and etoposide improve treatment outcomes in advanced ovarian cancer?
Conclusion
The study suggests that etoposide does not provide additional benefits to cisplatin as a treatment for advanced ovarian cancer.
Supporting Evidence
- 52% of evaluable patients showed a clinical response.
- Median survival time for responders was 19 months.
- Significant toxicity led to the removal of 16% of patients from the study.
Takeaway
Doctors tested a new medicine for women with a serious type of cancer, but it didn't help them get better.
Methodology
Patients received a combination of cisplatin and etoposide after meeting specific eligibility criteria, and their responses were evaluated after treatment.
Limitations
The study had a high proportion of patients with advanced disease, which may have affected the results.
Participant Demographics
Patients were mostly women with advanced epithelial ovarian cancer, aged 24 to 74, with a median age of 59.
Statistical Information
Confidence Interval
95% CI: 1.2-24 for CR, 10-41 for PR
Want to read the original?
Access the complete publication on the publisher's website